Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the...
Vous n'êtes pas connecté
Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy. However, the effect depends on which mutations the patient’s tumour carries. This is shown by results from the ProBio study, led by researchers at Karolinska Institutet in Sweden. The findings are [...]
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the...
Prostate cancer is the second most common cancer among men worldwide, following lung cancer. In the United States alone, nearly 300,000 new cases are...
Prostate cancer is the second most common cancer among men worldwide, following lung cancer. In the United States alone, nearly 300,000 new cases are...
A treatment paradox has recently come to light in prostate cancer: Blocking testosterone production halts tumour growth in early disease while...
Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced...
Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced...
Discover the SOLARIS trial findings on high-dose Vitamin D3 for metastatic colorectal cancer. Learn about its impact on treatment and potential...
Discover the SOLARIS trial findings on high-dose Vitamin D3 for metastatic colorectal cancer. Learn about its impact on treatment and potential...
Learn about the key findings from Blood Cancer UK's new report on improving survival rates and addressing disparities in blood cancer care.
Rates of prostate cancer across Europe since 1980 are “indicative of overdiagnosis”, say researchers in a study published by The BMJ ....